Skip to main content

Table 5 Progression free survival and overall survival

From: Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study

  ITT population (N = 45) Evaluable population (N = 43) PR Population (N = 45) SD Population (N = 45)
Median PFS (95 % CI) 8.2 mo (6–10.8) 8.2 mo (6–10.8) 9.96 mo (8.03-17.38) 6.16 mo (3.9-16.95)
Median OS (95 % CI) 36.6 mo (23.8-45.8) 36.6 mo (23.8-45.8) 41.48 mo (23.21-NA) 36.62 mo (17.51-NA)
  1. Abbreviations: CI, confidence interval; ITT, intent-to treat; mo, months; NA, not available; PFS, progression-free survival; PR, partial response; SD, stable disease